1. Home
  2. NSPR vs SERA Comparison

NSPR vs SERA Comparison

Compare NSPR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$1.20

Market Cap

72.1M

Sector

Health Care

ML Signal

HOLD

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

HOLD

Current Price

$2.00

Market Cap

79.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSPR
SERA
Founded
2005
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Precision Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.1M
79.5M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
NSPR
SERA
Price
$1.20
$2.00
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
55.0K
17.6K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
32.32
EPS
N/A
N/A
Revenue
$2,310,000.00
$81,000.00
Revenue This Year
$57.98
$554.81
Revenue Next Year
$95.41
$517.27
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.19
52 Week Low
$1.12
$1.37
52 Week High
$2.93
$4.09

Technical Indicators

Market Signals
Indicator
NSPR
SERA
Relative Strength Index (RSI) 27.44 42.40
Support Level N/A $1.91
Resistance Level $2.47 $2.41
Average True Range (ATR) 0.09 0.15
MACD -0.00 -0.02
Stochastic Oscillator 34.22 10.23

Price Performance

Historical Comparison
NSPR
SERA

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: